These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32977672)

  • 21. Targeting drug delivery to the lungs by inhalation.
    O'Callaghan C
    Mediators Inflamm; 1994; 3(7):S31-3. PubMed ID: 18475601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Air and soul: the science and application of aerosol therapy.
    Rubin BK
    Respir Care; 2010 Jul; 55(7):911-21. PubMed ID: 20587104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization.
    Qi A; Friend JR; Yeo LY; Morton DA; McIntosh MP; Spiccia L
    Lab Chip; 2009 Aug; 9(15):2184-93. PubMed ID: 19606295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs.
    Nadithe V; Rahamatalla M; Finlay WH; Mercer JR; Samuel J
    J Pharm Sci; 2003 May; 92(5):1066-76. PubMed ID: 12712427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler.
    Farr SJ; Warren SJ; Lloyd P; Okikawa JK; Schuster JA; Rowe AM; Rubsamen RM; Taylor G
    Int J Pharm; 2000 Mar; 198(1):63-70. PubMed ID: 10722951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
    Bäckman P; Arora S; Couet W; Forbes B; de Kruijf W; Paudel A
    Eur J Pharm Sci; 2018 Feb; 113():41-52. PubMed ID: 29079338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent aerosol delivery to the lungs during high-flow nasal cannula therapy.
    Golshahi L; Longest PW; Azimi M; Syed A; Hindle M
    Respir Care; 2014 Oct; 59(10):1476-86. PubMed ID: 24917454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery.
    Martin AR; Moore CP; Finlay WH
    Expert Opin Drug Deliv; 2018 Dec; 15(12):1175-1188. PubMed ID: 30388902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in aerosolised drug delivery.
    Chandel A; Goyal AK; Ghosh G; Rath G
    Biomed Pharmacother; 2019 Apr; 112():108601. PubMed ID: 30780107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
    Okuda T
    Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing challenges in respiratory therapies.
    Yeung S; Traini D; Lewis D; Young PM
    Int J Pharm; 2018 Sep; 548(1):659-671. PubMed ID: 30033395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
    Togami K; Chono S; Morimoto K
    J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):110-5. PubMed ID: 22360316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
    Delvadia RR; Longest PW; Hindle M; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aerosol drug delivery to the lungs during nasal high flow therapy: an in vitro study.
    Wallin M; Tang P; Chang RYK; Yang M; Finlay WH; Chan HK
    BMC Pulm Med; 2019 Feb; 19(1):42. PubMed ID: 30767769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
    Lim JG; Shah B; Rohatagi S; Bell A
    Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches to enhance pulmonary delivery of proteins and peptides.
    Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):615-25. PubMed ID: 18204175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle.
    de Boer AH; Le Brun PP; van der Woude HG; Hagedoorn P; Heijerman HG; Frijlink HW
    Eur J Pharm Biopharm; 2002 Jul; 54(1):17-24. PubMed ID: 12084498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aerosol drug delivery: developments in device design and clinical use.
    Dolovich MB; Dhand R
    Lancet; 2011 Mar; 377(9770):1032-45. PubMed ID: 21036392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
    Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
    Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novolizer: how does it fit into inhalation therapy?
    Magnussen H
    Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.